In 2025, Virbac’s annual revenue reached €1,465 million, up by 7.9% at constant exchange rates compared to 2024. Strong growth in pet (+10.9%) and livestock (+6.1%) categories was driven by a volume/mix effect of approximately +5% and a price increase of about +3%. The U.S. saw a solid growth of +14.7% at constant rates, followed by other regions.

For 2026, Virbac targets revenue growth between 5.5% and 7.5% at constant exchange rates, with an adjusted operating margin around 17%. The acquisition of Thyronorm is expected to contribute to these objectives.

Virbac’s CEO, Paul Martingell, highlighted the positive momentum in 2025, with strong organic growth of 7.9%. The company’s commitment to animal health was evident through successful product launches and strategic initiatives like the acquisition of Thyronorm, aimed at enhancing its portfolio for feline health.

Regionally, Europe showed a strong organic growth of +9.8%, driven by both pet and livestock segments. Americas saw positive growth, with North America at +5.5% and Latin America at +2.7%. IMEA registered a robust growth of +12.6%, while Asia East grew by +3.3% and the Pacific region remained stable.

In the fourth quarter of 2025, Virbac’s consolidated revenue reached €362 million, showing a strong growth of +7.1% at constant rates. Europe, IMEA, and the Pacific region led the growth, while Asia East saw a decline. The company’s strategic acquisitions contributed to the overall positive performance.

Virbac continues its strategic acquisitions with the recent purchase of Thyronorm, a specialized product for treating feline hyperthyroidism. This acquisition complements Virbac’s existing portfolio and is expected to positively impact sales and EBITDA margin. The company aims to enhance distribution in key regions to maximize the product’s potential.

Looking ahead to 2026, Virbac anticipates revenue growth between 5.5% and 7.5% at constant rates, with an operating margin around 17%. The acquisition of Thyronorm is factored into these projections, contributing positively to both revenue and operational results. Virbac is prepared for potential challenges like U.S. tariff impacts.

Read more at GlobeNewswire: solide croissance en 2025 avec un chiffre